Skip to main content
Gedea Biotech

Why this biotech startup from Lund University is ready to go global

Case study grow globally

Gedea Biotech has developed a major new antibiotic-free treatment for vaginal infections and is about to take its product on the world stage. And before Gedea was ready to release its transformative treatment, Invest in Skåne was there to help the fledgling business secure the transformative funding it needed and more. 

Discovered by a research team of three chemists and a gynaecologist at Lund University, the treatment called pHyph can be used for bacterial infections. In a recently finalised clinical trial pHyph shows 82% cure rate after one week of treatment (Data on file, 2020).

“This cure rate is similar to that typically achieved with existing antibiotic-based treatments.  pHyph intends to be the first antibiotic-free product that effectively prevents and treats bacterial vaginosis,” says Annette Säfholm, CEO of Gedea Biotech.  

According to Säfholm, Gedea’s product effectively treats bacterial vaginosis and will be available without a prescription and sold over-the-counter (OTC). Today, bacterial vaginosis is treated with antibiotics and one out of two patients have a recurrent episode of bacterial vaginosis within 90 days of treatment. Vaginal fungal infection is also common after treatment with antibiotics because antibiotics harm the protective bacteria. Gedea believes that pHyph will help restore the vaginal bacterial flora and thereby reduce the risk of recurrent BV and treatment-induced fungal infections significantly.

The WHO (World Health Organisation) sees antibiotic resistance as one of the most significant threats to global health. When antibiotics are present, antibiotic resistance will occur, sooner or later. By reducing the use of antibiotics, it will at least be later.

“It feels incredibly exciting and motivating to be working with women’s health where we really need investments in new products, as well as working with alternatives to antibiotics,” says CEO Annette Säfholm.

Next stop: world-wide pharmaceutical sales

Säfholm explains that Gedea’s goal is to reach global distribution as quickly as possible, with Europe set as their first market for approval to be sold over the counter. More clinical trials are needed to be available in the United States, but Säfholm says the company’s next scheduled trials are specifically designed to meet the requirement for the U.S. market.

Gedea wants to find a global pharmaceutical company to handle the marketing and sales of pHyph. “Our intention is not to market and sell ourselves,” explains Säfholm. “We will be able to reach patients quicker than if you would try to build up sales channels on your own.”

“...Since the competition is extremely high, it is necessary to consult others for help.”

Initially backed by LU Holding, the investment arm of Lund University’s innovation department that invests in startups based on research done at the university, Gedea Biotech has been approved for EU-funding, through Horizon 2020's Fast Track to Innovation (FTI) programme. 

Invest in Skåne helped Gedea in many different ways, and Säfholm says one of the organisation’s instrumental support was in the assistance with their application for the Horizon SME Instrument Phase 1 which then led on to the funding. The company had applied twice for the SME programme, but after Invest in Skåne’s individual consulting – they were approved.

Last year, Gedea received the EU-funded Fast Track to Innovation grant which provided the financial support for a larger placebo controlled study. The study will commence in the autumn of 2020.

Anette Säfholm


“The applications are difficult to write. That’s why it’s important to talk to those that know how to since the competition is extremely high. It is necessary to consult others for help”, says CEO Annette Säfholm.

“There is a lot of knowledge here…”

According to Säfholm, the core advantage of being based in Skåne is its wealth of expertise and knowledge to tap into, including local networks in areas and fields that are perfect for a company like Gedea.

“We’re located in Medicon Village, a unique location for networks related to pharmaceutical companies and technical companies. There is a lot of knowledge here and seminars that are good for development and networks with other companies makes it easy to find collaborators”, says Säfholm,

Säfholm says Gedea has found assistance for almost every conceivable organisational function, from support for clinical studies to advice on regulatory aspects, and even things like patent law and bookkeeping.

How Invest in Skåne helped Gedea Biotech

“We have received a lot of help from Invest in Skåne in regards to reaching out to investors and finding partner companies, and support in participating in international conferences,” says Annette Säfholm, CEO of Gedea Biotech.

And she also cites assistance in Gedea’s application for the Horizon SME Instrument Phase 1 funding as having a big impact.

Horizon SME, which is run by the European Union, provides funding and advisory services to startups. According to Säfholm, Gedea had applied once, but had not been accepted into the program. After Invest in Skåne advised them on their application – the company was approved and received €50,000 in funding.

“The applications are difficult to write,” she explains. “That’s why it’s important to talk to those that know how to since the competition is extremely high. It is necessary to consult others for help.”